Could better lung function help your patients focus on life beyond COPD? 1-3
Key trial design
Need help with this product?
Footnotes
BD, twice daily; BUD, budesonide; CAT, COPD assessment test; CI, confidence interval; FEV1, forced expiratory volume in one second; FF, fluticasone furoate; FOR, formoterol; ICS, inhaled corticosteroid; LABA, long-acting ß2-agonist; LAMA, long-acting muscarinic antagonist; LS, least squares; OD, once daily; MCID, minimal clinically important difference; SGRQ, St George’s Respiratory Questionnaire; UMEC, umeclidinium; VI, vilanterol
TRELEGY Ellipta OD is indicated for maintenance treatment in adult patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an ICS and a LABA.1
References
- Trelegy Ellipta Local Prescribing information based on EMEA V1.
- Lipson DA et al. Am J Crit Care Med 2017; 196:438–446.
- Lipson DA et al. N Engl J Med 2018; 378:1671–1680.
- Rebordosa C et al. Pharmacoepidemiol Drug Saf 2019; 28:126–133, including supplementary material.
- Jones PW et al. Am J Respir Crit Care Med 2014; 189:250–255.
- GSK, Data on File. RF/TLY/0067/18. IMPACT Study: trough FEV1 data over 52 weeks.
© 2020 GSK Group of Companies or its licensor
Trademarks are the property of their respective owners
TRELEGY Ellipta was developed in collaboration with
PM-SA-FVU-WCNT-200010 Date of preparation: September 2020